Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gourzones, Claire, Bellanger, Céline, Lamure, Sylvain, Gadacha, Ouissem Karmous, De Paco, Elvira Garcia, Vincent, Laure, Cartron, Guillaume, Klein, Bernard, Moreaux, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521290/
https://www.ncbi.nlm.nih.gov/pubmed/30925767
http://dx.doi.org/10.3390/cancers11040439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521290/
https://www.ncbi.nlm.nih.gov/pubmed/30925767
http://dx.doi.org/10.3390/cancers11040439

Ejemplares similares